Page 7 of 7
« First‹ Prev567

Health Economics and Outcomes Research (HEOR) (136 POSTS)

2014 (7 POSTS)

A U.S. hospital budget impact model for oritivancin in ABSSSI patients with risk of MRSA infections

Wu C, Fortier K, Fan WJ, LePensse K, Bay CB, Cyr PL, Jensen IS. A U.S. hospital budget impact model for oritivancin in ABSSSI patients with risk of MRSA infections. ISPOR 16th Annual European Congress, Amsterdam, Netherlands, 2014.

Estimating the value of cangrelor from eliminating preloading in coronary artery bypass graft (CABG) patients

Bay C, Cyr PL, Jensen IS. Estimating the value of cangrelor from eliminating preloading in coronary artery bypass graft (CABG) patients. ISPOR 16th Annual European Congress, Amsterdam, Netherlands, 2014.

Increased use of plerixafor in patients with multiple myeloma and non-Hodgkin’s lymphoma in the United States: A budgetary impact analysis

Jensen IS, Halbert RJ, Thompson SF, Hennessy D, Pacconi S, McSweeney PA. Increased use of plerixafor in patients with multiple myeloma and non-Hodgkin’s lymphoma in the United States: A budgetary impact analysis. Abstract C14, Academy of Managed Care Pharmacy 26th Annual Meeting & Expo, 2014.

View Abstract

2013 (5 POSTS)

Incorporating stakeholder input into budget impact models to compare stem cell mobilization strategies

Jensen IS, Halbert RJ, Grosvenor A, Swartz E, Rossi G, Naoshy S, et al. Incorporating stakeholder input into budget impact models to compare stem cell mobilization strategies. Abstract PCN43, ISPOR 18th Annual International Meeting, 2013.

View Abstract

The economic burden of treatment-resistant depression

Olchanski N, McInnis-Myers M, Halseth M, Cyr PL, Bockstedt L, Goss TF, Howland RH. 2013. The economic burden of treatment-resistant depression. Clin Ther 35(4):512-522; doi: 10.1016/j.clinthera.2012.09.001.

View Abstract

Avoidable costs in U.S. healthcare: The $200 billion opportunity from using medicines more responsibly

Sacks NC. 2013. Avoidable costs in U.S. healthcare: The $200 billion opportunity from using medicines more responsibly. IMS Health, June.

View Abstract

Cost sharing and decreased branded oral anti-diabetic medication adherence among elderly Part D Medicare beneficiaries

Sacks NC, Burgess JF, Cabral HJ, Pizer SD, McDonnell, ME. 2013. Cost sharing and decreased branded oral anti-diabetic medication adherence among elderly Part D Medicare beneficiaries. J Gen Intern Med 28(7):876–885.

View Abstract

Dual-acting osmotic and stimulant laxative for bowel cleansing in an elderly population: A US payer budget impact analysis

Cyr P, Sidhu M, Hussain R, Hromin T, Jensen I, Kuan R. Dual-acting osmotic and stimulant laxative for bowel cleansing in an elderly population: A US payer budget impact analysis. Abstract PCN22, ISPOR 18th Annual International Meeting, 2013.

View Abstract

2012 (2 POSTS)

A German hospital budget impact model comparing antibiotic therapies in complicated skin and skin structure infections and bacteremia

Jensen I, Ogborne R, Cyr P. A German hospital budget impact model comparing antibiotic therapies in complicated skin and skin structure infections and bacteremia. ISPOR 17th Annual International Meeting, 2012.

Impact of complications in solid organ transplants on hospital charges and length of stay

Jensen I, Helm T, Cyr P. Impact of complications in solid organ transplants on hospital charges and length of stay. Abstract PSU15, ISPOR 17th Annual International Meeting, 2012.

View Abstract

2011 (2 POSTS)

Impact of dysphagia on U.S. hospital charges in patients with comorbid conditions

Jensen I, Helm T, Cyr P. Impact of dysphagia on U.S. hospital charges in patients with comorbid conditions. Abstract PGI9, ISPOR 14th Annual European Congress, 2011.

View Abstract

Impact of complications from dysphagia on hospital charges in the United States

Jensen I, Helm T, Cyr P. Impact of complications from dysphagia on hospital charges in the United States. Abstract PGI7, ISPOR 14th Annual European Congress, 2011.

View Abstract

2010 (1 POST)

Economic impact of switching to bivalirudin for a primary percutaneous coronary intervention in a U.S. hospital

Olchanski N, Slawsky KA, Plent S, Kado C, Cyr PL. 2010. Economic impact of switching to bivalirudin for a primary percutaneous coronary intervention in a U.S. hospital. Hosp Prac 38(4):138-146; doi: 10.3810/hp.2010.11.351.

View Abstract

2009 (2 POSTS)

A web-based nutrition program reduces health care costs in employees with cardiac risk factors: Before and after cost analysis

Sacks NC, Cabral HJ, Kazis LE, Richmond R, Vetter D, Moore TM. 2009. A web-based nutrition program reduces health care costs in employees with cardiac risk factors: Before and after cost analysis. J Med Internet Res 23:11(4):e43; doi: 10.2196/jmir.1263.

View Abstract

Healthcare spending among privately insured individuals under age 65

Sacks NC. 2009. Healthcare spending among privately insured individuals under age 65. IMS Health, February.

2004 (1 POST)

Realities at the leading edge of research

Alexander W, Berlin J, Cyr PL, Schofield A, Platt LA. 2004. Realities at the leading edge of research. EMBO Rep 5(4):324-329; doi: 10.1038/sj.embor.7400137.

View Abstract
Page 7 of 7
« First‹ Prev567